Supplementary Figure 12 from Intratumoral Sotigalimab with Pembrolizumab Induces Rapid Activation of Antigen-Presenting Cells and Drives Antitumor Responses in Non-injected Tumors in Metastatic Melanoma: A Phase I/II Study
Year: 2026
Type: supplementary-materials
Abstract: Clinical responses to the combination of sotigalimab and pembrolizumab do not require MHC class II expression or IFN-g–mediated immune activation at baseline
Authors: Salah-Eddine Bentebibel, Daniel J. McGrail, Veena Kochat, Emre Arslan, Reham Abdel-Wahab, Barbara Pazdrak, Ravi Murthy, Nourel Hoda M. Tahon, Sung-Nam Cho, Dzifa Y. Duose, Khalida M. Wani, Jingjing Liu, Cara Haymaker, Javier A. Gomez, Heather Sonnemann, Arjun S. Katailiha, Barbara Nassif-Rausseo, Maha Rahim, Irene Li, Aaron T. Mayer, Xiaodong Yang, Frank J. Hsu, Jianhua Zhang, Daniel H. Johnson, Rodabe N. Amaria, Isabella C. Glitza Oliva, Sapna P. Patel, Patrick Hwu, Khaled M. Elsayes, Hussein A. Tawbi, Jared K. Burks, Chantale Bernatchez, Michael A. Davies, Kunal Rai, Gregory Lizée, Suhendan Ekmekcioglu, Adi Diab
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7204879597
Cites:
Cited by:
Related to: